Enzo Biochem (NYSE:ENZ) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ) in a research report sent to investors on Sunday morning. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Performance

ENZ opened at $0.48 on Friday. The company’s 50-day simple moving average is $0.55 and its two-hundred day simple moving average is $0.86. Enzo Biochem has a 52-week low of $0.41 and a 52-week high of $1.30.

Enzo Biochem (NYSE:ENZ) last posted its earnings results on Monday, March 17th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter. The company had revenue of $7.33 million for the quarter. Enzo Biochem had a negative net margin of 75.34% and a negative return on equity of 7.96%.

Institutional Investors Weigh In On Enzo Biochem

Several hedge funds and other institutional investors have recently made changes to their positions in ENZ. Virtu Financial LLC purchased a new stake in shares of Enzo Biochem during the 4th quarter valued at about $35,000. Lepercq Multi Asset Fund purchased a new stake in shares of Enzo Biochem during the 4th quarter valued at about $88,000. BBR Partners LLC purchased a new stake in shares of Enzo Biochem during the 3rd quarter valued at about $112,000. Wittenberg Investment Management Inc. increased its position in shares of Enzo Biochem by 60.1% during the 4th quarter. Wittenberg Investment Management Inc. now owns 187,537 shares of the medical research company’s stock valued at $134,000 after purchasing an additional 70,400 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Enzo Biochem by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after purchasing an additional 11,742 shares during the last quarter. Hedge funds and other institutional investors own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.